Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pasritamig + docetaxel
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Pasritamig + docetaxel is an investigational combination therapy being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Pasritamig (JNJ-78278343) is a first-in-class, bispecific T-cell-engaging antibody that targets human kallikrein 2 (KLK2), a prostate-specific antigen, and CD3 on T cells, thereby redirecting T cells to selectively destroy KLK2-expressing prostate cancer cells. Docetaxel is an established taxane chemotherapy that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis. The combination is designed to leverage the cytotoxic effects of chemotherapy alongside targeted immunotherapy to improve outcomes in patients whose disease has progressed after treatment with an androgen receptor pathway inhibitor (ARPI). In clinical trials, the combination has demonstrated a manageable safety profile consistent with docetaxel monotherapy and encouraging clinical activity, including high rates of prostate-specific antigen (PSA) response.
- Other names
- JNJ-78278343 + docetaxelJNJ-78278343 plus docetaxelJNJ78278343 plus docetaxelJNJ 78278343 plus docetaxeldocetaxel + pasritamigdocetaxel plus pasritamigpasritamig + docetaxelpasritamig plus docetaxel
02
Targets
CD3 (T-cell surface glycoprotein CD3)HK2 (Hexokinase Type II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pasritamig + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pasritamig + docetaxel.